Skip to content
10-K

Annual Report

Akero Therapeutics, Inc.

0000950170-25-029514

← back to feed
Filed
Feb 28, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 14, 2025 79.62M sh
Shares Diluted FY 2024 · Dec 31, 2024 67.14M sh
Shares Diluted FY 2024 · Dec 31, 2023 52.57M sh
Shares Diluted FY 2024 · Dec 31, 2022 38.98M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$230.11M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$145.37M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$92.52M
Cash And Equivalents FY 2024 · Dec 31, 2024 $340.24M
Cash And Equivalents FY 2024 · Dec 31, 2023 $234.21M
Stockholders Equity FY 2024 · Dec 31, 2024 $750.11M
Stockholders Equity FY 2024 · Dec 31, 2023 $535.31M
Stockholders Equity FY 2024 · Dec 31, 2022 $326.56M
Stockholders Equity FY 2024 · Dec 31, 2021 $169.11M
Current Liabilities FY 2024 · Dec 31, 2024 $39.75M
Current Liabilities FY 2024 · Dec 31, 2023 $19.13M
Total Liabilities FY 2024 · Dec 31, 2024 $75.77M
Total Liabilities FY 2024 · Dec 31, 2023 $44.97M
Current Assets FY 2024 · Dec 31, 2024 $770.38M
Current Assets FY 2024 · Dec 31, 2023 $559.96M
Total Assets FY 2024 · Dec 31, 2024 $825.89M
Total Assets FY 2024 · Dec 31, 2023 $580.27M
Eps Diluted FY 2024 · Dec 31, 2024 −$3.75
Eps Diluted FY 2024 · Dec 31, 2023 −$2.89
Eps Diluted FY 2024 · Dec 31, 2022 −$2.87
Eps Basic FY 2024 · Dec 31, 2024 −$3.75
Eps Basic FY 2024 · Dec 31, 2023 −$2.89
Eps Basic FY 2024 · Dec 31, 2022 −$2.87
Sga Expense FY 2024 · Dec 31, 2024 $37.93M
Sga Expense FY 2024 · Dec 31, 2023 $31.07M
Sga Expense FY 2024 · Dec 31, 2022 $29.87M
Rd Expense FY 2024 · Dec 31, 2024 $247.5M
Rd Expense FY 2024 · Dec 31, 2023 $141.8M
Rd Expense FY 2024 · Dec 31, 2022 $85.28M
Net Income FY 2024 · Dec 31, 2024 −$252.06M
Net Income FY 2024 · Dec 31, 2023 −$151.76M
Net Income FY 2024 · Dec 31, 2022 −$112.03M
Operating Income FY 2024 · Dec 31, 2024 −$285.42M
Operating Income FY 2024 · Dec 31, 2023 −$172.87M
Operating Income FY 2024 · Dec 31, 2022 −$115.16M